Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of...
-
Upload
archibald-jacobs -
Category
Documents
-
view
215 -
download
1
Transcript of Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of...
![Page 1: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/1.jpg)
Amjad Fathi Hussein El-ShantiMD, MPH, Doctorate of Public Health (Epidemiology)
Medical director of CFFC-Gaza
April-2014
![Page 2: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/2.jpg)
Contents
• Introduction:Definition of Cystic fibrosis (CF)Epidemiology of CF ( Magnitude and Genotype Distribution)Pathogenesis of CFClinical Manifestations of CFDiagnosis of CFTreatment
• CF in Gaza Strip• Conclusion• Recommendations
![Page 3: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/3.jpg)
![Page 4: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/4.jpg)
What is cystic fibrosis (CF)?• A multisystem disease• Autosomal recessive inheritance• Cause: mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR)– chromosome 7 – codes for a c-AMP regulated chloride channel
Rosenstein, BJ and Zeitlin, PL. Cystic fibrosis. The Lancet. 351: 277-82.
•A multisystem disease
•Autosomal recessive inheritance
What is cystic fibrosis (CF)?
Rosenstein, BJ and Zeitlin, PL. Cystic fibrosis. The Lancet. 351: 277-82.
Definition
![Page 5: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/5.jpg)
Autosomal recessive inheritance in CF
Let C= normal CFTRLet c= mutant CFTRIf mom and dad are both
carriers then:
• With mom and dad carriers, then:– 50% chance of having
child who is a carrier– 25% chance of child
being affected– 25% of child with no
mutant copies of CFTRCC
Cc
Cc
cc
C c
C
c
![Page 6: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/6.jpg)
Definition• Cystic Fibrosis (CF) or mucoviscidosis is an
inherited disease of the exocrine glands, primarily affecting the GI and respiratory systems, and usually characterized by COPD, exocrine pancreatic insufficiency, and abnormally high sweat electrolytes, causing progressive disability and often, early death.
• It is caused by a mutation in a gene called the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
![Page 7: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/7.jpg)
Epidemiology of Cystic Fibrosis
![Page 8: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/8.jpg)
• Birth prevalence is traditionally cited as 1 in 2,000 to 1 in 2,500 live births in Caucasian populations.
• For Non-Caucasian countries, the problem of estimating birth prevalence of CF is even greater, and good estimates are lacking.
Magnitude and genotypic distribution
![Page 9: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/9.jpg)
• In UK, in 2003, the prevalence of CF was of 11.7 per 100,000.
• In Canada, the prevalence was 10.5 per 100,000 (based on 2002 patient registry data and 2005 population estimates).
Magnitude and genotypic distribution
![Page 10: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/10.jpg)
• The incidence of CF among Arabs is estimated to range from rare to as common as the Caucasian populations.
• Reports indicated frequencies ranging from 1:5800 in Bahrain, to 1:2650 in Jordan.
• In Egypt, CF is more common than previously anticipated with an incidence rate of 1:2664.
Magnitude and Genotypic Distribution
![Page 11: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/11.jpg)
• The commonest mutation identified in the world is DF508, which comprises 66% of global mutations, followed by G451X and G551D which are responsible for 2.4% and 1.6% of the mutations respectively.
Magnitude and Genotypic Distribution
![Page 12: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/12.jpg)
• Survival and mortality rate are useful indicators of clinical outcome, and are likely to be influenced by a variety of factors.
• The CDR for CF in 2003 in the UK is only 0.17 per 100,000 general population.
• In USA, standardized mortality has been shown to vary significantly with genotype, being as low as 4.4 per 1000 person-years at risk for certain genotype combination and as high as 25 per 1000 for others.
Magnitude and genotypic distribution:
![Page 13: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/13.jpg)
• Non genetic factors:1. Gender2. Skin color and race3. Birth weight4. Consanguinity5. Socioeconomic status6. Environmental factors7. Patient adherence to prescribed medical regimens
• Genetic Factors:1. CFTR gene mutations2. Modifying genes
Risk factors & determinants
![Page 14: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/14.jpg)
Pathogenesis of CF
![Page 15: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/15.jpg)
Pathogenesis
• The CFTR gene is found in region q31.2 on the long (q) arm of human chromosome 7.
![Page 16: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/16.jpg)
Gibson, RL, Burns, JL, and Ramsey, BW. Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. AJRCCM 168 (918-951); 2003.
CFTR Gene and Protein
![Page 17: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/17.jpg)
Pathogenesis• The CFTR protein transports chloride ions (Cl-) ions
across the membranes of cells of the lungs, liver, pancreas, digestive tract, reproductive tract, and skin.
• It is made up of five domains:
![Page 18: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/18.jpg)
Types of mutations in CFTR• Class I
– Defective protein production• Class II
– Defects in processing• ΔF508
• Class III– CFTR reaches cell surface but
regulation is defective (channel not activated)
• Class IV– CFTR in membrane with
defective conduction• Class V
– Decreased synthesis of CFTRhttp://www.cysticfibrosismedicine.com/htmldocs/CFText/genetics.htm
![Page 19: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/19.jpg)
Pathogenesis
• Mutations in the CFTR gene have been classified into five different groups according to the mechanism by which they disrupt CFTR function.
ClassEffect on CFTR proteinExample of mutation
IShortened proteinW1282X
IIProtein fails to reach cell membrane
ΔF508
IIIChannel cannot be regulated properly
G551D
IVReduced chloride conductance
R117H
VReduced due to incorrect splicing of gene
3120+1G>A
![Page 20: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/20.jpg)
5 Classes of CFTR Mutations
20
II
Defective
Processing
III
Defective
Regulation
IV
Defective
Conductance
V
Reduced
Amounts
I
Defective
Production
![Page 21: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/21.jpg)
CFTR and Airway Surface Liquid
Donaldson,SH and Boucher,RC. Update on the pathogenesis of cystic fibrosis lung disease.
Current Opinion in Pulmonary Medicine. 9: 486-491; 2003.
![Page 22: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/22.jpg)
Airway surface liquid low volume hypothesis
• Mucus---helps clear airway of bacteria• Clearance of mucus depends on
– Ciliary function– Mucin secretion – Volume of airway surface liquid (ASL)
• Forms periciliary liquid layer• Dilutes mucus---facilates entrapment of bacteria and
clearance• Optimal volume of ASL regulated by Na+ absorption
and Cl- secretionDonaldson,SH and Boucher,RC. Update on the pathogenesis of cystic fibrosis lung disease.
Current Opinion in Pulmonary Medicine. 9: 486-491; 2003.
![Page 23: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/23.jpg)
• Normal CFTR inhibits a sodium channel (ENaC)– Mutant CFTR----ENaC not inhibited
• Sodium absorption is increased• Water follows sodium• ASL volume decreases
• Normal CFTR will cause Cl- ions to be secreted if the ASL fluid is low– Mutant CFTR Cl- ions not secreted
Donaldson,SH and Boucher,RC. Update on the pathogenesis of cystic fibrosis lung disease.Current Opinion in Pulmonary Medicine. 9: 486-491; 2003.
Airway surface liquid low volume hypothesis
![Page 24: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/24.jpg)
• Cilia do not beat well when PCL volume is depleted
• Mucins are not diluted and cannot be easily swept up the airway
• Mucus becomes concentrated• Results in increased adhesion to airway surface• Promotes chronic infection
Donaldson,SH and Boucher,RC. Update on the pathogenesis of cystic fibrosis lung disease.Current Opinion in Pulmonary Medicine. 9: 486-491; 2003.
Airway surface liquid low volume hypothesis
![Page 25: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/25.jpg)
25
The mutant form of CFTR prevents chloride transport, causing mucus build-up
Mucus clogs the airwaysMucus clogs the airways
and disrupts the function ofand disrupts the function of
the pancreas & intestinesthe pancreas & intestines . .
From Mutation To Disease
![Page 26: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/26.jpg)
Pathophysiology of CF
CFTR Dysfunction
Disease manifestations
– Lungs
– Sinuses
– Pancreas
– Liver
– Bones
– Vas deferens
??
![Page 27: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/27.jpg)
Clinical Manifestations of CF
![Page 28: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/28.jpg)
• Chronic Sino-Pulmonary Disease• Nutritional deficiency/GI abnormality• Obstructive Azoospermia• Electrolyte abnormality • CF in a first degree relative
Cystic Fibrosis Foundation. Clinical Practice Guidelines for Cystic fibrosis.1997.
![Page 29: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/29.jpg)
![Page 30: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/30.jpg)
Chronic Sino-Pulmonary Disease
• Chronic infection with CF pathogens • Endobronchial disease
– Cough/sputum production– Air obstruction---wheezing; evidence of obstruction on
PFTs– Chest x-ray anomalies– Digital Clubbing
• Sinus disease– Nasal Polyps– CT or x-ray findings of sinus disease
Cystic Fibrosis Foundation. Clinical Practice Guidelines for Cystic fibrosis.1997.
![Page 31: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/31.jpg)
Infection
Gibson, RL, Burns, JL, and Ramsey, BW. Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. AJRCCM 168 (918-951); 2003.
![Page 32: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/32.jpg)
Prevalence of Infections in CF Patients
00
2020
4040
6060
8080
100100
00 to 1to 1 22 to 5to 5 66 to 10to 10 1111 to 17to 17 1818 to 24to 24 2525 to 34to 34 3535 to 44to 44 4545++
Age (years)Age (years)
Per
cen
tP
erce
nt
Cystic Fibrosis Foundation Patient Registry Data. 2005
P. aeruginosaP. aeruginosa
S. aureusS. aureus
MRSAMRSA
H. influenzaH. influenza
S. maltophiliaS. maltophilia B. cepaciaB. cepacia
![Page 33: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/33.jpg)
CF Infections---Pseudomonas aeruginosa
• 80% CF patients eventually infected with pseudomonas
• Association between acquiring pseudomonas and clinical status deterioration
• Form biofilms• Relatively large genome
– Pseudomonae collected from sputa of CF patients have been noted to have larger genomes than lab strains
Gibson, RL, Burns, JL, and Ramsey, BW. AJRCCM 168 (918-951); 2003.
![Page 34: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/34.jpg)
Pseudomonas genome
http://www.pseudomonas.com/
![Page 35: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/35.jpg)
Burkholderia cepacia complex
• B. cepacia syndrome: fevers, rapidly progressive necrotizing pneumonia, death
• Chronic cepacia infection decreased lung function and increased mortality
• Several closely related species termed genomovars1
Holmes, A, Govan, J, and Goldstein, R. Agricultural Use of Burkholderia (Pseudomonas) cepacia: A Threat to Human Health?Emerging Infectious Diseases. 4(2):221-227; 1998
1. Gibson, RL, Burns, JL, and Ramsey, BW. AJRCCM 168 (918-951); 2003.
![Page 36: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/36.jpg)
Endobronchial disease
• Hyperinflation• Peribronchial cuffing• Bronchiectasis• Diffuse fibrosis • Atelectasis
From: http://www.meddean.luc.edu/lumen/meded/elective/pulmonary/cf/cf_f.htm
![Page 37: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/37.jpg)
Nasal Polyps
• Benign lesions in nasal airway
• If large enough, can be associated with significant nasal obstruction, drainage, headaches, snoring
• Likely associated with chronic inflammation
• May need surgical intervention
• High recurrence rate
From :http://www.emedicine.com/ped/topic1550.htm
![Page 38: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/38.jpg)
Digital Clubbing
• Bulbous swelling at end of fingers
• Normal angle between nail and nail bed lost (Schamroth sign)
• Can be associated with pulmonary disease, cardiac disease, ulcerative colitis, and malignancies
From: Fawcett et al., 2004
![Page 39: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/39.jpg)
Nutritional deficiency• Pancreatic insufficiency
• Pancreatic enzymes stay in ducts and are activated intraductally
– Autolysis of pancreas– Inflammation, calcification, plugging of ducts,
fibrosis
• Malabsorption– Failure to thrive– Fat soluble vitamin deficiency
1. Davis, P. Cystic Fibrosis Since 1938. AJRCCM Articles in Press. Doi: 10.1164/rccm.200505-840OE; 2005.2. Quinton, P. Physiologic Basis of Cystic Fibrosis. Physiol Rev 79:3-22, 1999.
![Page 40: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/40.jpg)
GI disease
• Intestinal abnormality– Meconium ileus– Distal intestinal obstruction syndrome (DIOS)– Rectal prolapse
• Hepatobiliary disease– Focal biliary cirrhosis– Multilobular cirrhosis
• Pancreatic endocrine dysfunction– Cystic fibrosis related diabetes
![Page 41: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/41.jpg)
Cystic fibrosis related liver disease• Focal inspissation of bile
– Obstructs biliary ductules
• Second leading cause of death in CF1
• Prevalence 9-37%1
• Spectrum of disease – increased liver enzymes – biliary cirrhosis – portal hypertension
1. Efrati, O et al., Liver Cirrhosis and portal hypertension in CF. European Journal of Gastroenterology and Hepatology. 15(10): 1073-1078; 2003.
![Page 42: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/42.jpg)
Cystic fibrosis related diabetes mellitus
• Screening– Oral glucose tolerance test (OGTT)
• Every two years in patients 10-16 years• Any patient with random plasma glucose >180
• Fasting>=140 mg/dl– initiate insulin treatment
• Fasting<140 and OGTT at 2 hrs>200 mg/dl– Home glucose monitoring; consider insulin
• Fasting <140 and 2 hour 140-200– Impaired glucose tolerance
• OGTT annually• Fasting and 2 hour <140
– Normal glucose tolerance
![Page 43: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/43.jpg)
Infertility
• Men– Abnormal embryologic development of the
epididymal duct and vas deferens---may be incomplete of absent1
– Congential bilateral absence of the vas deferens—97-98% of men with CF 1
1. Lewis-Jones et al, Cystic fibrosis in infertility: screening before assisted reproduction: Opinion. Human Reproduction 15(11): 2415-2417.
![Page 44: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/44.jpg)
Infertility• Women
– Lower fertility rate than non-CF women– Viscid mucoid cervical secretions of low volume in
women with CF 1
• Pregnancy and CF: – Goss et al, 2003---no significant difference in
survival in women who became pregnant with CF compared to women who did not become pregnant (after adjusting for disease severity)2
1.Quinton, P. Physiologic Basis of Cystic Fibrosis. Physiol Rev 79:3-22, 19992.Goss, CH, Rubenfeld, GD, Otto, K and Aitken, ML. The effect of pregnancy on survival in women with cystic fibrosis. Chest 124(4):1460-68; 2003.
![Page 45: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/45.jpg)
Electrolyte abnormality---history• Dr. Paul di Sant’ Agnese
– 1949 NYC heat wave----noted CF infants to have a higher rate of heat prostration than non-CF
• Showed that sodium and chloride concentration in CF patients’ sweat was 5 times higher than in non-CF1
– Became basis for sweat chloride test
.1Davis, P. Cystic Fibrosis Since 1938. American Journal of Respiratory and Critical Care Medicine Vol 173. pp. 475-482, (2006)
![Page 46: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/46.jpg)
Electrolyte abnormality
• Clinically---hypochloremic metabolic alkalosis– CFTR on luminal side of sweat duct
• Chloride goes in from lumen via CFTR and out to blood by other transporters
• Sodium goes in via ENaC• Defective CFTR---Na and Cl- movement and
reabsoprtion into lumen impeded
Goodman, B and Percy, WH..CFTR in Teaching Membrane Transport. Adv Physiol Educ. 29 (79-82); 2005
![Page 47: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/47.jpg)
Genetic Determinants of severity of disease
• The variability in disease severity in patients with CF is not a consequence of relative preservation of pancreatic function but is a result of different gene mutants, together with additional factors, genetic and /or environmental.
• The location of a mutation along the CFTR gene has no direct effect on severity of CF disease.
![Page 48: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/48.jpg)
• One or more clinical manifestations of CF PLUS• Two CF mutations OR• Two positive quantative pilocarpine
iontophoresis sweat chloride values OR• An abnormal nasal transepithelial potential
difference value
Diagnosis of Cystic Fibrosis
![Page 49: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/49.jpg)
Diagnostic criteria for cystic fibrosis
Part 1: Clinical Manifestation of Disease• At least one of the following:
1) One or more clinical manifestations of CF• Meconium ileus• Chronic bronchitis / bronchiectasis• Chronic infection of the paranasal sinuses• Pancreatic insufficiency• Salt loss syndromes• Male infertility due to congenital bilateral absence of the vas deferens
2) Positive newborn screening test3) History of CF in a sibling
![Page 50: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/50.jpg)
Diagnostic Criteria for Cystic FibrosisPart 2: Laboratory evidence of CFTR abnormality
• At least one of the following: 1) Elevated sweat chloride test
2) Identification of a mutation in each CFTR gene known to cause CF
3) In vivo demonstration of characteristic abnormalities in ion transport across nasal epithelium (not widely available)
![Page 51: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/51.jpg)
Sweat Test
![Page 52: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/52.jpg)
Sweat Test for Diagnosis of CF
0 20 40 60 80 100 120 140 160 180
mEq/L
0
300
600
900
1200
1500
1800
0
600
120
180
240
Nu
mb
er o
f n
orm
al c
on
tro
ls
Nu
mb
er o
f p
atie
nts
wit
h C
F
Controlsn=4269
CFn=920
Shwachman H, Mahmoodian A. Mod Prob Pediatr 1967;10:158
![Page 53: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/53.jpg)
A perspective on the Sweat Test• The “sweat test” provides laboratory confirmation
of the clinical diagnosis of Cystic Fibrosis.
• This occurs because of an abnormally high salt concentration in their eccrine sweat, ranging from 3-5 times higher than that of normal children.
![Page 54: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/54.jpg)
A perspective on the Sweat Test• The sweat Test was first described in 1959 by
Gibson & Cooke and remains the “ Gold Standard” for the diagnosis of cystic fibrosis.
• In the majority of CF patients with typical features and identified CFTR mutations, the sweat test is diagnostic.
• In atypical forms, the sweat chloride levels may fall into the intermediate range and there are rare examples of patients with CF, confirmed on genetic testing, who have a normal sweat test.
![Page 55: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/55.jpg)
SWEAT TESTING PROCEDURE WESCOR MACRODUCT
Sweat Stimulus & Collection
Sweat Analysis
![Page 56: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/56.jpg)
Sweat chloride
–Positive Sweat chloride: 60-165 meq/L
–Borderline sweat chloride: 40-60 meq/L
–Normal sweat chloride: 0-40
![Page 57: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/57.jpg)
Sweat chloride• False positives:
– Anorexia Nervosa– Autonomic dysfunction– Addison disease– Ectodermal dysplasia– Eczema– Edema– Fucosidosis– Glucose-6-Phosphate dehydrogenase deficiency– Glycogen storage disease Type 1– Hypothyroidism– Hypoparathyroidism– Malnutrition from various causes including HIV infection– Nephrogenic diabetes insipidus– Nepohrosis– Lab error (evaporation or contamination of sample)
Davis, P. Cystic Fibrosis Since 1938. AJRCCM Articles in Press. Doi: 10.1164/rccm.200505-840OE; 2005.
![Page 58: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/58.jpg)
Sweat Chloride• False negatives:
– Edema– Malnutrition– Some CF mutations– Sample diluted
Davis, P. Cystic Fibrosis Since 1938. AJRCCM Articles in Press. Doi: 10.1164/rccm.200505-840OE; 2005.
![Page 59: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/59.jpg)
Use of Genotyping to Diagnose CF
• 1601 CFTR mutations known to cause CF
• Only 25 mutations have a frequency > 0.1%
FrequencyFrequency% ,% ,
00 1010 2020 3030 4040 5050 6060 7070
R347PR347P3849+10kbC 3849+10kbC T T
ΔΔ I507 I507R117HR117H
R1162XR1162X1717-1G 1717-1G A A
R553XR553X621+1G 621+1G T T
W1282XW1282XN1303KN1303KG551DG551DG542XG542XΔΔF508F508
CF Genetic Analysis Consortium
Population Frequency of Specific CFTR Mutations Causing CFPopulation Frequency of Specific CFTR Mutations Causing CF
![Page 60: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/60.jpg)
Genotyping for CF Diagnosis
• Current commercial screening tests
– Look for presence of between 25 - 100 mutations
– These will detect a CF allele only ~90% of time
• For a group of patients with known CF, genotyping would be diagnostic in only ~81% of patients
• Screening for most common mutations is not as sensitive as sweat testing (98%) to diagnose classic CF
![Page 61: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/61.jpg)
Genetic Diagnosis of CF
• Tests becoming commercially available for detecting mutations more broadly– PCR used to amplify all exons and surrounding
splice sites– Heteroduplex formation screening and/or
sequencing– Analysis for large deletions and duplications
![Page 62: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/62.jpg)
Treatment
![Page 63: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/63.jpg)
It gets more complicated......
![Page 64: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/64.jpg)
Treatment
•The only way to cure CF would be to use gene therapy to replace the defective gene or to give the patient the normal form of the protein before symptoms cause permanent damage.
![Page 65: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/65.jpg)
• The major goal in treating CF is:1. to clear the abnormal and excess secretions and 2. to control infections in the lungs, and3. to prevent obstruction in the intestines.
• For patients with advanced stages of the disease, a lung transplant operation may be necessary.
• Although treating the symptoms does not cure the disease, it can greatly improve the quality of life for most patients and has, over the years, increased the average life span of CF patients to 30 years.
![Page 66: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/66.jpg)
Treatment of Acute Exacerbations of CF Lung Disease
• Antibiotic treatment– Oral antibiotics
• If symptoms are mild, and• Bacteria are susceptible
– Intravenous antibiotics otherwise
![Page 67: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/67.jpg)
Management of Chronic Lung Disease in Cystic Fibrosis
![Page 68: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/68.jpg)
Aerosolized Antibiotics
• High dose tobramycin proven for chronic infection–TOBI® 300 mg in 5 ml bid every other month
Ramsey B, et al. NEJM 1999;340:23-30
![Page 69: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/69.jpg)
Mucolytic Therapy for CF
• DNase (Pulmozyme ®)–Chronic use improves FEV1 and causes fewer exacerbations
Fuchs HJ, et al. NEJM 1994;331:637-642
![Page 70: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/70.jpg)
Bronchodilators in CF
• No studies in acute exacerbations but routinely given
• Chronic use -- FEV1 improves acutely in some patients– -adrenergic agonists (e.g. albuterol, salmeterol)– Anticholinergic agents (ipratroprium bromide,
tiotroprium)
![Page 71: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/71.jpg)
Anti-Inflammatory Treatment in CF
• Glucocorticoids– Oral (prednisone)
• Preserves lung function, but too many adverse effects
– Inhaled• Used for subgroup of with bronchial hyperreactivity
(asthma) symptoms
• Ibuprofen– Beneficial for young patients– No evidence for improvement in adults
![Page 72: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/72.jpg)
Macrolide Therapy for CF
• Azithromycin in CF– Improved FEV1– Fewer exacerbations of CF
lung disease– Uncertain mechanism of
action• Anti-inflammatory?• Bacterial toxin or biofilm
production? 00 44 1212 2424 2828
--44
--22
00
22
4455
Study WeekStudy Week
AzithromycinAzithromycin
PlaceboPlacebo
11
--11
--33
33
Ch
ang
e in
FE
VC
han
ge
in F
EV
11 (%
pre
dic
ted
) (
% p
red
icte
d)
88 1616 2020
Saiman L, et al. JAMA. 2003;290:1749-56
![Page 73: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/73.jpg)
Nebulized Hypertonic Saline (7%)
Elkins MR et al. N Engl J Med 2006;354:229-240
• Effect on FEV1
– Randomized, double-blind, placebo controlled trial
– N = 164
– Inhalation of 4 ml of 7% vs. 0.9% saline bid for 48 weeks
![Page 74: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/74.jpg)
Effect of 7% Saline on Frequency of Pulmonary Exacerbations
Elkins MR et al. N Engl J Med 2006;354:229-240
![Page 75: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/75.jpg)
Physiotherapy for CF
• No studies in acute exacerbations– But “standard of care” treatment
• Beneficial for chronic management
![Page 76: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/76.jpg)
Gastrointestinal Treatment Modified diet • Due to pancreatic disorders, children with CF
require a modified diet, including vitamin supplements (vitamins A, D, E, and K) and pancreatic enzymes.
• Maintaining adequate nutrition is essential. The diet calls for a high-caloric content (twice what is considered normal for the child's age), which is typically low in fat and high in protein.
• Patients or their caregivers should consult with their health care providers to determine the most appropriate diet.
![Page 77: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/77.jpg)
Gene Therapy
• Gene therapy is the use of normal DNA to "correct" for the damaged genes that cause disease.
• In the case of CF, gene therapy involves inhaling a spray that delivers normal DNA to the lungs.
• The goal is to replace the defective CF gene in the lungs to cure CF or slow the progression of the disease.
![Page 78: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/78.jpg)
![Page 79: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/79.jpg)
• The average annual incidence rate of CF disease through the last ten years (2000-2010) in the Gaza strip was 1.26 case per 5000 live births.
Magnitude of CF disease in GS
Incidence rates of cystic fibrosis disease (Gaza, 2000- 2010)
![Page 80: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/80.jpg)
• The average annual prevalence of CF disease through the last ten years in Gaza strip was 3.72 cases per 100,000 population.
Magnitude of CF disease in GS
Prevalence rates of cystic fibrosis disease (Gaza, 2000- 2010)
![Page 81: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/81.jpg)
Mortality
• The average annual mortality rate due to CF in the Gaza Strip through the last ten years (2000-2010) was 0.26 case per 100,000 populations.
• The average annual CFR of CF through the last ten years was 9.18%.
Magnitude of CF disease in GS
![Page 82: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/82.jpg)
CF diagnosis• The mean age of CF cases at diagnosis was 6.05+6.57 months. (98%
of cases were infants at time of diagnosis).
Magnitude of CF disease in GS
![Page 83: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/83.jpg)
Clinical manifestations and hospitalizations of CF patients• All cases were recurrently admitted to hospital, The average
admission times was 3.51+1.63 times/year among cases.
Magnitude of CF disease in GS
Distribution of cystic fibrosis cases by the affected systems (Gaza,2010)
![Page 84: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/84.jpg)
Nutritional indicators of CF cases and controls
Magnitude of CF disease in GS
Variable
Cases (n= 100) Controls (n= 100)T-Test
AverageS.DAverageS.DTP
Height (cm)99.6420.10112.1016.6
2-4.780.000*
HAZ-2.42
1.800.07
2.09-9.010.000*
Weight (kg)14.70
5.8419.89
7.44-5.480.000*
WAZ-2.48
1.05-0.26
1.67-11.280.000*
WHZ-1.67
1.82-0.02
2.06-5.980.000*
Average anthropometric measurements and nutritional indicators of cystic fibrosis cases and controls (Gaza, 2010)
*Statistically significant
![Page 85: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/85.jpg)
Nutritional indicators of CF cases and controls• This difference was a statistically significant (t=-13.71, p =0.00).
Magnitude of CF disease in GS
Average hemoglobin level of CF cases and controls (Gaza, 2010)
![Page 86: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/86.jpg)
• Male Gender (OR=2.35, 95% CI=1.26, 4.04, p=0.004). • Fair Skin Color (OR=5.43, 95% CI=2.11, 14.50, p=0.000).• Consanguinity (OR=13.20, 95% CI=5.94, 29.95, p=0.000). • North Gaza Governorate (OR=2.006,95%CI=1.04,3.853, p=0.035).
Risk factors associated with CF disease in GS
Distribution of cases and controls by sociodemographic factors (Gaza, 2010)
Sociodemographic factors
![Page 87: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/87.jpg)
Genetic determinants of CF disease in GS
• The results of mutation testing revealed that 61% of known mutation-CF cases have at least single allele of F508.
• Also 12.2% of known mutation-CF cases were of homo 3120+1kb CFTR mutation.
• Also 14.7% of known mutation-CF cases were of homo N1303k CFTR mutation, homo G85E CFTR mutation, and homo 3120del 18.6kb CFTR mutation equally.
![Page 88: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/88.jpg)
Genetic determinants of CF disease in GS
CF disease ClassesCF Cases
No%
Class I24.9
Class II2151.2
Class III00
Class IV12.4
Class V819.5
Compound922
Total41100
![Page 89: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/89.jpg)
![Page 90: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/90.jpg)
• The majority of the cases was diagnosed during infantile age and was diagnosed in Governmental Pediatric Hospitals by both manifestations and sweat test.
![Page 91: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/91.jpg)
• The anthropometric measurements and hemoglobin level of CF cases in the GS reflected that short stature, underweight, wasting and anemia were very common.
• About two thirds of known mutation of CF cases have at least a single allele of DF508, which is considered of severe type of CFTR mutations.
![Page 92: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/92.jpg)
RECOMMENDATIONS
![Page 93: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/93.jpg)
Recommendations concerning CF services
• Neonatal screening programs for CF disease should be set up.
• The importance of establishing a reliable diagnosis of CF using a properly conducted sweat test. In addition, diagnostic radiology, and laboratory facilities.
• Integration of genetic counseling and services for CF cases’ families into primary health care.
![Page 94: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/94.jpg)
• Setting an expanded comprehensive health educational program for families of CF cases’, old CF cases, and general public about CF and strengthening the nutrition program for the public.
• Supplies of pancreatic enzymes and basic antibiotics, including anti-Pseudomonas agents for CF patients free of charge .
• It is essential for health authorities to know the magnitude of the problem if they are to make appropriate provisions for CF care.
• It is important to establish and maintain a national CF registry in order to identify and predict the need for services and to monitor survival trends.
![Page 95: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/95.jpg)
Recommendations for improving socioeconomic & environmental status
• Increasing the situation of women in the community by encouraging the high education of girls, and involving the women in all fields and works.
• Increasing community awareness and counseling concerning the effect of early marriage and consanguineous marriage.
![Page 96: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/96.jpg)
• Campaigns aiming at educating families on the importance of clean drinking water as well as advising mothers to take compensatory measures such as additional nutrition intakes.
• Local authorities should inform the public about local concentrations of air pollutants, possible effects on health, and the action taken to minimize any health risks.
![Page 97: Amjad Fathi Hussein El-Shanti MD, MPH, Doctorate of Public Health (Epidemiology) Medical director of CFFC-Gaza April-2014.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649e2d5503460f94b1dc43/html5/thumbnails/97.jpg)